NicOx partners with Bausch & Lomb for its candidate glaucoma drug

Article

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
Related Content
A microphone in a stand is lit by a spotlight, shining on an empty stage. Image credit: ©Who is Danny – stock.adobe.com

See what our Editorial Advisory Board members are bringing to EURETINA

Hattie Hayes
September 12th 2024
Article

Spotlight on the retina specialists who make up the Eye Care Network advisory boards

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
The Earth with the EURETINA logo superimposed on top. Image credit: ©dimazel – stock.adobe.com and EURETINA

Celebrate World Retina Day at the 2024 EURETINA Congress

Hattie Hayes
September 10th 2024
Article

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

Placa Reial in Barcelona, Spain. A fountain is lit up by streetlamps. Tourists gather at night. Image credit: ©JackF – stock.adobe.com

24th EURETINA Congress: The art of retina on stage in Barcelona

Lynda Charters
September 10th 2024
Article

Focus on collaboration, career development and innovation

Ramin Tadayoni speaks at the 2023 EURETINA Congress. Image courtesy EURETINA.

Remembering a legend: EURETINA members speak about the Ramin Tadayoni Award

Hattie Hayes
September 9th 2024
Article

The Ramin Tadayoni Award supports the next generation of retina researchers while paying tribute to a leader in the field

A cell being injected by a syringe. Image credit: ©Corona Borealis – stock.adobe.com

Trinity team’s gene therapy offers promising glaucoma and AMD treatment

Martin David Harp
September 9th 2024
Article

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

© 2024 MJH Life Sciences

All rights reserved.